Life Sciences & Medicine Active Updated Oct 7, 2026
Weight-loss drugs and everything else they do
Where it stands as of Oct 7, 2026
GLP-1 drugs keep turning up effects that reach beyond the scale, including a possible calorie-burning brown fat mechanism, altered reward-seeking in mice, and now signs of slower biological aging. Novo Nordisk and Eli Lilly reported at a conference that patients on the drugs had aging clocks two to three years younger than placebo, up to 4 years by some measures. These are the companies' own readouts, and no one knows whether the clocks move in people who are not already sick.
The GLP-1 drugs are turning out to change mood, behavior and the brain's relationship with food, not just body weight, as coverage expands to older adults.
Oct 7, 2026 Latest
Novo Nordisk and Eli Lilly presented data at the Aging Research & Drug Discovery conference showing that overweight or diabetic patients on GLP-1 drugs had a lower biological age than those on placebo, as measured by molecular aging clocks. Novo's Nikolaj Roed put the overall gap at two to three years, varying by clock and organ and reaching as much as 4 years, and UCLA's Steve Horvath called two years 'a pretty strong effect.'
Oct 6, 2026
Nautilus reported that in mice, a brief exposure to the cytokine TGF-β1 left fat cells making more of the appetite hormone asprosin for weeks, which may explain weight regain after GLP-1 drugs stop. Knocking out asprosin and its receptor erased the effect, and human replication is still needed.
Oct 1, 2026
PsyPost reported that semaglutide altered reward-seeking behavior in healthy mice, and ScienceAlert ran a piece on whether Ozempic-like drugs could affect alcohol cravings.
Sep 27, 2026
A study found Zepbound and Mounjaro, two GLP-1 drugs, may activate the body's calorie-burning brown fat, ScienceDaily reported.
Sep 24, 2026
A study found nearly 1 in 6 children taking GLP-1 weight loss and diabetes drugs developed nutritional deficiencies, ScienceDaily reported.
Sep 22, 2026
A study found that stopping Ozempic (semaglutide) may raise the risk of heart attack and stroke, ScienceDaily reported.
Sep 19, 2026
PsyPost reported that mice given semaglutide before a bacterial inflammatory challenge still showed the initial immune spike but recovered from brain inflammation noticeably faster afterward, a pattern researchers said may help explain why patients on GLP-1 drugs appear to show lower dementia rates.
Sep 17, 2026
A Mendelian randomization study led by Guoyi Yang at the University of Pennsylvania, published in Translational Psychiatry, found that genetically proxied activation of the GLP-1 receptor was linked to better mental health, including a lower risk of depression and bipolar disorder and a possible protective effect against substance use disorders.
Sep 12, 2026
A study of 63,215 patients found that semaglutide's apparent mental health benefits tracked with dose rather than with how much weight patients lost, suggesting the drug may act directly on the brain independent of weight loss.
Sep 9, 2026
SingularityHub reported that semaglutide-treated elderly mice lived roughly 12 percent longer than untreated mice, with fewer senescent cells, cooled chronic inflammation, and new neuron growth in the hippocampus, and outside researcher Tara Spires-Jones at the University of Edinburgh called it a promising hint the effect could hold in people too.
Sep 6, 2026
A controlled trial found semaglutide cut heavy drinking days, drinks per drinking day and alcohol-related negative consequences for people with moderate to severe alcohol use disorder, though it did not improve every measure tested.
Sep 5, 2026
A follow-up report from Danica Chen's lab found that semaglutide-treated older female mice still outperformed untreated mice on cognitive tests even when both groups ate an identical strict diet, evidence that the drug's anti-aging effect is not simply a byproduct of eating less.
Sep 3, 2026
UC Berkeley researchers led by Danica Chen gave semaglutide to mice already 20 months old and found after three months improved muscle function, sharper spatial memory and lower inflammation markers than untreated controls, and lifelong treatment extended median lifespan by nearly 100 days, matching or beating calorie restriction, the oldest known lifespan-extending intervention, on most measures.
Aug 16, 2026
A Gallup report showed the US adult obesity rate falling to 36.4%, down from a peak of 39.9% in 2022, as the share of adults reporting current GLP-1 use for weight loss rose from 3% in 2024 to 11% in 2026, and Cambridge researchers found the reason different obesity drugs work is which brain region they touch, since activating the GIPR receptor in the brainstem and blocking it in the hypothalamus both cut appetite in mice.
Jul 17, 2026
A new study found GLP-1 receptor agonists reduced symptoms of binge eating, adding another behavioral effect to the drugs' expanding profile beyond weight loss.
Jul 15, 2026
A randomized, placebo-controlled trial of 108 adults living with HIV, led by Michael Corley at UC San Diego, found weekly semaglutide slowed biological aging across several epigenetic clocks tied to inflammation and the health of the blood, brain, heart, kidneys, liver and metabolism, including a 9 percent slower pace of aging on the DunedinPACE clock. People with HIV tend to age faster biologically even when the virus is well controlled, and the researchers said a much larger trial is needed before extending the finding beyond this population.
Jul 8, 2026
A 52-week trial of 1,698 adults across six countries found orforglipron, a new daily pill, outperformed oral semaglutide on both weight loss and blood sugar control. Unlike oral semaglutide, orforglipron requires no refrigeration and no empty stomach before dosing, and it is cheaper to manufacture, which could significantly expand access in lower-income countries where injectable GLP-1 drugs remain out of reach.
Jul 7, 2026
Cleveland Clinic researchers analyzed records from 2,133 people with type 2 diabetes and peripheral artery disease and found those prescribed GLP-1 receptor agonists like semaglutide had a 48 percent lower risk of major amputation, a 37 percent lower risk of minor amputation, and a 36 percent lower risk of circulation-restoring procedures over five years, compared to a matched metformin group. They were also 26 percent less likely to die from any cause. Whether the benefit comes from weight loss, blood sugar control, or a direct effect on blood vessel walls remains unclear.
Jun 21, 2026
A review found the drugs work well for most people but not all, with a minority seeing little benefit.
Jun 17, 2026
Reporting described GLP-1 drugs quieting the constant mental chatter about food known as food noise, as Medicare coverage began for adults 65 and older.
Jun 14, 2026
Research found GLP-1 weight-loss drugs change bodies in unexpected ways, including measurable drops in daily step counts.
The checkable promises in this story, dated the day they were made. A promise is marked kept, slipped or partly met only when a later report says so; past its own date with no report, it reads "no word", which is what silence honestly is.
GLP-1 drugs cut the risk of amputation and death in diabetics with peripheral artery disease, but whether the benefit comes from weight loss, blood sugar improvement, or a direct effect on blood vessel walls is unresolved and, the researchers say, deserves prospective trials.
Reporting in the Today Got Better brief
whether the benefit comes from weight loss, blood sugar improvement, or a direct effect on blood vessel walls is an open question the researchers say deserves prospective trials
When this question gets a new answer, the page above changes the same morning. Each morning's letter brings the day's progress in science, medicine and beyond. Free, every day.
Free forever, no spam. One click to unsubscribe, and we never sell your email.